Pre-made Oportuzumab benchmark antibody ( scFv, anti-EPCAM therapeutic antibody, Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-408

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-408 Category Tag

Product Details

Pre-Made Oportuzumab biosimilar, scFv, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity.

Products Name (INN Index)

Pre-Made Oportuzumab biosimilar, scFv, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody

INN Name

Oportuzumab

Target

EPCAM

Format

scFv

Derivation

NA

Species Reactivity

Human

CH1 Isotype

NA

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Preregistration

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2008

Companies

University of Zurich,National Cancer Institute (USA),Sesen Bio,Viventia Biotechnologies

Conditions Approved

NA

Conditions Active

Bladder cancer,Head and neck cancer

Conditions Discontinued

Liver cancer,Ovarian cancer

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

EPCAM

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide